Document is current
Any future updates will be listed below
-
Authors
Crum, Yoran
van Veldhuisen, Dirk J.
Lobeek, Michelle
Voors, Adriaan A.
Rienstra, Michiel
Gorter, Thomas M.
- License Information
-
More Information
Article History
Received: 4 November 2025
Accepted: 29 July 2026
First Online: 16 September 2026
Declarations
Conflict of interest: The University Medical Centre Groningen, which employs all the authors of this article, has received research grants and/or consultancy fees from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cytokinetics, Merck, Myokardia, Novartis, Novonordisk and Roche Diagnostics. A.A. Voors has received consultancy fees from Myokardia, Bayer, AstraZeneca, Merck and Boehringer Ingelheim. D.J. van Veldhuisen reports board membership fees/travel expenses from Johnson Johnson and Novartis. M. Rienstra reports unrestricted grants fromZonMW, the Dutch Heart Foundation; DECISIONproject 848090001, the Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation; RACE V (CVON 2014–9), RED-CVD (CVON2017-11) and the Top Sector Life Sciences Health to the Dutch Heart Foundation (PPP Allowance; CVON-AI (2018B017)). ICVGreports grants from the Dutch Heart Foundation (CVON RACE V, grant 2014-09). The UMCG, which employs M. Rienstra has received consultancy fees from Bayer and InCarda Therapeutics. T.M. Gorter is supported by the Mandema-Stipend of the Junior Scientific Masterclass 2020-10 of the University Medical Centre Groningen. Y. Crum and M. Lobeek, and declare that they have no competing interests.
